Asthma is a chronic inflammatory respiratory disease accompanied with airway inflammation, airway remodeling and bronchial hyperresponsiveness.  Chemokines are important for the recruitment of immune cells to the lung, which play an important role in the formation and development of asthma.  Targeting the chemokine receptors to anti-inflammation and anti-asthma is a new strategy and some candidate drugs are discovered recently.  This review is focused on the development of chemokine receptor antagonists for anti-asthma, which will promote the compound designations.